ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Use of a Latent Class Analysis in the Diagnosis of Chronic Chagas Disease in the Washington Metropolitan Area.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A Trypanosoma cruzi trans-sialidase peptide demonstrates high serological prevalence among infected populations across endemic regions.The Journal of clinical investigation · 2026Article
- Case Report: Donor-derived Chagas Disease Post-heart Transplant After False-negative DonorTransplantation direct · 2025Article
- An Evidence-Based Intervention to IncreaseOpen forum infectious diseases · 2025Article
- Immunologic changes in the peripheral blood transcriptome of individuals with early-stage chronic Chagas cardiomyopathy: a cross-sectional study.Lancet regional health. Americas · 2025Article
- Prevalence ofOpen forum infectious diseases · 2024Article
- Chagas Disease: Epidemiology, Diagnosis, and Treatment.Current cardiology reports · 2024Review
- Diversity of Chagas disease diagnostic antigens: Successes and limitations.PLoS neglected tropical diseases · 2024Review
- Chagas disease in the United States: a call for increased investment and collaborative research.Lancet regional health. Americas · 2024Review
- Article
- Assessment of Community Awareness and Screening of Chagas Disease in the Latin American Community of Greater New Orleans.Tropical medicine and infectious disease · 2023Article
- Case Report: A Case of Post-Transplant Chagas Reactivation after Negative Trypanosoma cruzi Testing.The American journal of tropical medicine and hygiene · 2023Article
- Concordance of Results by Three Chagas Disease Antibody Assays in U.S. Clinical Specimens.Journal of clinical microbiology · 2023Article
- Chagas Disease Prevalence in a Cohort of Neurocysticercosis Patients in a Nonendemic Setting.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Screening for Chagas Disease Should Be Included in Entry-to-Care Testing for At-Risk People With Human Immunodeficiency Virus (HIV) Living in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Updated Estimates and Mapping for Prevalence of Chagas Disease among Adults, United States.Emerging infectious diseases · 2022Review
- Recommendations for Screening and Diagnosis of Chagas Disease in the United States.The Journal of infectious diseases · 2022Article
- The Importance of Screening for Chagas Disease Against the Backdrop of Changing Epidemiology in the USA.Current tropical medicine reports · 2022Review
- Roadblocks in Chagas disease care in endemic and nonendemic countries: Argentina, Colombia, Spain, and the United States. The NET-Heart project.PLoS neglected tropical diseases · 2021Review
- Chagas Disease in HIV-Infected Patients: It's Time to Consider the Diagnosis.The American journal of tropical medicine and hygiene · 2021Article
- Comparative Performance of Latest-Generation and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease.Journal of clinical microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe diversity of individuals at risk for Trypanosoma cruzi infection in the United States poses challenges for diagnosis. We evaluated the diagnostic accuracy of Food and Drug Administration (FDA)-cleared tests in the Washington Metropolitan area (WMA).
methodsIn total, 1514 individuals were evaluated (1078 from Mexico, Central and northern South America [TcI-predominant areas], and 436 from southern South America [TcII/V/VI-predominant areas]). Optical density (OD) values from the Hemagen EIA and Chagatest v.3 Wiener, and categorical results of the IgG-TESA-blot (Western blot with trypomastigote excretory-secretory antigen), and the Chagas detect plus (CDP), as well as information of area of origin were used to determine T. cruzi serostatus using latent class analysis.
resultsWe detected 2 latent class (LC) of seropositives with low (LC1) and high (LC2) antibody levels. A significantly lower number of seropositives were detected by the Wiener, IgG-TESA-blot, and CDP in LC1 (60.6%, P < .001, 93.1%, P = .014, and 84.9%, P = .002, respectively) as compared to LC2 (100%, 100%, and 98.2%, respectively). LC1 was the main type of seropositives in TcI-predominant areas, representing 65.0% of all seropositives as opposed to 22.8% in TcII/V/VI-predominant areas. The highest sensitivity was observed for the Hemagen (100%, 95% confidence interval [CI]: 96.2-100.0), but this test has a low specificity (90.4%, 95% CI: 88.7-91.9). The best balance between positive (90.9%, 95% CI: 83.5-95.1), and negative (99.9%, 95% CI: 99.4-99.9) predictive values was obtained with the Wiener.
conclusionsDeficiencies in current FDA-cleared assays were observed. Low antibody levels are the main type of seropositives in individuals from TcI-predominant areas, the most frequent immigrant group in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.